作者：
Kyra J,Cowan [1]
;
Lysie,Champion [2]
;
Daniel,Dyer [3]
;
Morten Funch,Carlsen [4]
;
Laura,Geary [5]
;
Jean-Christophe,Genin [6]
;
Michaela,Golob [7]
;
Joanne,Goodman [8]
;
Arno,Kromminga [9]
;
Rob,Nelson [10]
;
Heather,Revell [3]
;
Martin,Rieger [11]
;
Ortwin,Van de Vyver [12]
;
Foka,Venema [13]
;
Philip,Timmerman [14]
作者单位：
Merck KGaA, Research & Development, Drug Metabolism & Pharmacokinetics New Biological Entities, Darmstadt, 64293, Germany.
[1]
Celerion Switzerland AG, Bioanalytical Services, Fehraltorf, 8320, Switzerland.
[2]
Labcorp, Immunochemistry Method Development, Harrogate, HG3 1PY, UK.
[3]
LEO Pharma, Bioanalysis & Pharmacokinetics, Ballerup, 2750, Denmark.
[4]
Resolian Bioanalytics, Immunoassay Bioanalysis, Fordham, CB7 5WW, UK.
[5]
F. Hoffmann-La Roche Ltd (Roche Innovation Center Basel), Basel, 4058, Switzerland.
[6]
Nuvisan GmbH, Bioanalysis, Neu-Ulm, 89231, Germany.
[7]
Bioanalytical Services, Celerion, Lincoln, NE 68502, USA.;AstraZeneca, Cambridge, CB21 6GH, United Kingdom.
[8]
Biolytics, BioNTech SE, Mainz, 55131, Germany.
[9]
BioAgilytix Laboratories, Hamburg, 22339, Germany.
[10]
MorphoSys AG, Clinical Pharmacology, Planegg, 82152, Germany.
[11]
Sanofi, Drug Metabolism & Pharmacokinetics, Zwijnaarde, 9052, Belgium.
[12]
Ardena Bioanalysis, AJ Assen, 9403, The Netherlands.
[13]
European Bioanalysis Forum vzw (EBF), Havenlaan 86c b204, Brussels, 1000, Belgium.
[14]
DOI
10.1080/17576180.2024.2376950
PMID
39101618
发布时间
2024-10-10
换一批
换一批
